Protagonist Therapeutics Inc
PTGX98.970USD
-3.200-3.13%
Cierre 03/27, 16:00（ET）Cotizaciones retrasadas 15 min
1.45BCap. mercado
PérdidaP/E TTM
Más Datos de Protagonist Therapeutics Inc Compañía
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
Información de Protagonist Therapeutics Inc
Símbolo de cotizaciónPTGX
Nombre de la empresaProtagonist Therapeutics Inc
Fecha de salida a bolsaAug 11, 2016
Director ejecutivoPatel (Dinesh V)
Número de empleados126
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 11
Dirección7707 Gateway Blvd Ste 140
CiudadNEWARK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94560-1160
Teléfono15104740170
Sitio Webhttps://www.protagonist-inc.com/
Símbolo de cotizaciónPTGX
Fecha de salida a bolsaAug 11, 2016
Director ejecutivoPatel (Dinesh V)
Ejecutivos de Protagonist Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
368.12K
+14.93%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+5.79%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
55.72K
+30.50%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
3.68K
-32.40%
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
2.69K
--
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
2.69K
--
Mr. William D. Waddill
Mr. William D. Waddill
Independent Director
Independent Director
--
--
Mr. Bryan M. Giraudo
Mr. Bryan M. Giraudo
Independent Director
Independent Director
--
--
Dr. Arturo Molina, M.D.
Dr. Arturo Molina, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Corey Davis, Ph.D.
Mr. Corey Davis, Ph.D.
IR Contact Officer
IR Contact Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Dinesh V. Patel, Ph.D.
Dr. Dinesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
368.12K
+14.93%
Mr. Suneel Gupta, Ph.D.
Mr. Suneel Gupta, Ph.D.
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
244.41K
+5.79%
Dr. Harold E. (Barry) Selick, Ph.D.
Dr. Harold E. (Barry) Selick, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
55.72K
+30.50%
Mr. Asif Ali
Mr. Asif Ali
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
3.68K
-32.40%
Dr. Lewis T. Williams ,M.D., Ph.D.
Dr. Lewis T. Williams ,M.D., Ph.D.
Independent Director
Independent Director
2.69K
--
Ms. Sarah A. O'Dowd
Ms. Sarah A. O'Dowd
Independent Director
Independent Director
2.69K
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: vie., 20 de feb
Actualizado: vie., 20 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
13.04%
Farallon Capital Management, L.L.C.
9.63%
The Vanguard Group, Inc.
8.47%
RTW Investments L.P.
7.93%
State Street Investment Management (US)
5.01%
Otro
55.92%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
13.04%
Farallon Capital Management, L.L.C.
9.63%
The Vanguard Group, Inc.
8.47%
RTW Investments L.P.
7.93%
State Street Investment Management (US)
5.01%
Otro
55.92%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
41.23%
Investment Advisor/Hedge Fund
40.19%
Hedge Fund
20.26%
Venture Capital
3.84%
Research Firm
3.78%
Private Equity
2.25%
Pension Fund
1.90%
Individual Investor
1.12%
Bank and Trust
0.38%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
592
74.88M
119.78%
-4.87M
2025Q3
551
71.95M
115.09%
-3.63M
2025Q2
533
68.00M
109.30%
-9.94M
2025Q1
541
67.25M
108.51%
-8.96M
2024Q4
503
65.58M
106.87%
-12.21M
2024Q3
480
64.24M
108.98%
-11.36M
2024Q2
419
61.14M
104.21%
-15.61M
2024Q1
412
61.98M
106.36%
-12.46M
2023Q4
402
59.53M
103.21%
-16.02M
2023Q3
400
59.06M
102.70%
-14.36M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
8.02M
12.83%
-434.20K
-5.13%
Sep 30, 2025
Farallon Capital Management, L.L.C.
6.20M
9.91%
+24.00K
+0.39%
Sep 30, 2025
The Vanguard Group, Inc.
4.25M
6.79%
-101.37K
-2.33%
Sep 30, 2025
RTW Investments L.P.
5.76M
9.21%
--
--
Sep 30, 2025
State Street Investment Management (US)
3.17M
5.06%
-41.75K
-1.30%
Sep 30, 2025
Wellington Management Company, LLP
1.91M
3.05%
+870.71K
+83.90%
Sep 30, 2025
UBS Financial Services, Inc.
1.89M
3.03%
-608.94K
-24.35%
Sep 30, 2025
Janus Henderson Investors
1.10M
1.76%
+653.99K
+146.36%
Sep 30, 2025
Johnson & Johnson Innovation-JJDC, Inc.
2.45M
3.92%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
1.42M
2.27%
-27.58K
-1.91%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
Invesco S&P SmallCap Health Care ETF
2.82%
Invesco S&P SmallCap 600 Pure Growth ETF
2.71%
Invesco Dorsey Wright Healthcare Momentum ETF
2.33%
ALPS Medical Breakthroughs ETF
1.99%
ETC 6 Meridian Small Cap Equity ETF
1.56%
State Street SPDR S&P Biotech ETF
1.44%
Cambria Value and Momentum ETF
1.16%
Invesco S&P SmallCap Momentum ETF
1%
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
Direxion Daily S&P Biotech Bull 3X Shares
0.88%
Ver más
Invesco S&P SmallCap Health Care ETF
Proporción2.82%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporción2.71%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción2.33%
ALPS Medical Breakthroughs ETF
Proporción1.99%
ETC 6 Meridian Small Cap Equity ETF
Proporción1.56%
State Street SPDR S&P Biotech ETF
Proporción1.44%
Cambria Value and Momentum ETF
Proporción1.16%
Invesco S&P SmallCap Momentum ETF
Proporción1%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.94%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.88%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
